iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus Gets USFDA Nod for Dasatinib Tablets

6 Mar 2025 , 03:27 PM

Zydus Lifesciences Ltd has bagged final approval from the US Food and Drug Administration (USFDA) to produce and market Dasatinib tablets in the US. The approved strengths are 20 mg, 50 mg, 70 mg, 80 mg, 100 mg and 140 mg.

Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). According to IQVIA MAT data (January 2025), Sprycel® tablets recorded annual sales of $1.81 billion in the US market.

The medication is primarily prescribed for:

  • Newly diagnosed adults with Ph+ CML in the chronic phase.
  • Patients with chronic, accelerated, or blast phase Ph+ CML who have shown resistance or intolerance to previous treatments.
  • Adults with Ph+ ALL who have not responded well to prior therapies.

Dasatinib tablets will be manufactured at Zydus’ Ahmedabad SEZ facility. With this latest approval, Zydus has now secured a total of 415 regulatory approvals from the USFDA. However, the company has also submitted 483 ANDAs since the FY 03-04 (as of December 31, 2024).

Shares of Zydus Lifesciences Ltd is currently trading at ₹906.40 which is a 2.14% gain than the previous close, The stock has witnessed a total of 5.76% dip in the last one year, and 10% dip in the last one year.

Related Tags

  • USFDA nod
  • Zydus
  • Zydus Approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

SBI Card Q4 Profit Slips 20%
25 Apr 2025|11:17 PM
HUL Q4 Net Profit Rises to ₹2,493 Crore
25 Apr 2025|10:59 PM
Sensex and Nifty in Red on April 25, 2025
25 Apr 2025|02:08 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.